Tempus AI, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 12, 2025 Deadline to file Lead Plaintiff Motion.

Core Viewpoint - Tempus AI, Inc. is facing a class action lawsuit due to allegations of misleading statements and undisclosed material information during the Class Period from August 6, 2024, to May 27, 2025 [1][3]. Company Overview - Tempus AI is a technology company focused on advancing precision medicine through artificial intelligence, including generative AI [2]. Allegations of the Lawsuit - The lawsuit claims that Tempus AI inflated the value of certain contract agreements, many involving related parties, which included non-binding opt-ins or were self-funded [3]. - It is alleged that the company's joint venture with SoftBank Group Corporation risked credibility due to the appearance of "round-tripping" capital to artificially inflate revenue [3]. - The acquisition of Ambry Genetics Corporation is said to have operated under a business model reliant on aggressive and potentially unethical billing practices, exposing it to regulatory and financial risk [3]. - AstraZeneca PLC reportedly reduced its financial support to Tempus AI through a questionable "pass-through payment" structure involving a joint agreement with Pathos AI, Inc. [3]. - These issues are indicative of broader weaknesses in Tempus AI's core operations and long-term revenue outlook [3]. Impact on Stock Price - Following the publication of a research report by Spruce Point Capital Management, LLC on May 28, 2025, which raised serious concerns regarding Tempus AI's management and financial disclosures, the company's stock price fell by over 19% [4].